FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

ì	pe Response			I													
Name and Address of Reporting Person* MANZO MICHAEL P.				2. Issuer Name and Ticker or Trading Symbol EYEGATE PHARMACEUTICALS INC [EYEG]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X Officer (give title below) Other (specify below)						
(Last) (First) (Middle) C/O EYEGATE PHARMACEUTICALS, INC., 271 WAVERLEY OAKS ROAD, SUITE 108				3. Date of Earliest Transaction (Month/Day/Year) 07/02/2020								VI	P of Enginee	ering			
(Street) WALTHAM, MA 02452				4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person _Form filed by More than One Reporting Person							
(City) (State) (Zip)				Table I - Non-Derivative Securities Acqui						ired, Disposed of, or Beneficially Owned							
1.Title of Security (Instr. 3)			2. Transaction Date (Month/Day/Year)			(Instr. 8)		4. Securities Acquir (A) or Disposed of (Instr. 3, 4 and 5)			Beneficia Reported	nt of Securities ally Owned Following Transaction(s)		Ownership Form:	ip of Be	Beneficial	
				(Month/Day/Ye	ar)	Code	v	Amou	nt (A)		Price	(Instr. 3 a	nd 4)		Direct (I or Indire (I) (Instr. 4)	/	wnership nstr. 4)
Common Stock 0		07/02/2020			F ⁽¹⁾	97 D \$ 4.82		.82	17,885			D					
Reminder:	Report on a s	separate line fo	r each class of secur Table II - 1	Derivative Secur			Per cor the	sons w tained form di	ho res in this isplays	forns a c	n are urrei	not requ ntly valid	ction of inf uired to res OMB conf	spond unle	ess	C 147	74 (9-02)
Ι	ı	T		e.g., puts, calls,	war	rants, o	-							Ι			
Security	2. Conversion or Exercise Price of Derivative Security		Execution Da Year) any	e, if Transaction Notes (Instr. 8) In Code Code Code Code Code Code Code Code		Number		6. Date Exercisable and Expiration Date (Month/Day/Year)		Amo Undo Secu	tle and bunt of erlying rities r. 3 and	f Derivative g Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction((Instr. 4)	Owner Form Deriv Secur Direct or Ind	rative rity: t (D) lirect	Beneficia	
				Code V	7 ((A) (D		e ercisable	Expira Date	ation	Title	Amount or Number of Shares					

Reporting Owners

	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
MANZO MICHAEL P. C/O EYEGATE PHARMACEUTICALS, INC. 271 WAVERLEY OAKS ROAD, SUITE 108 WALTHAM, MA 02452			VP of Engineering				

Signatures

/s/ Sarah Romano, Attorney-in-Fact*	07/06/2020		
Signature of Reporting Person	Date		

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Sale of shares to cover taxes due on restricted stock that vested on 07/01/2020.

Remarks:

*Signed under power of attorney on behalf of Reporting Person

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.